Structure–activity relationship study of syringolin A as a potential anticancer agent
- 1 November 2015
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (21) , 4872-4877
Abstract
No abstract availableKeywords
Funding Information
- JSPS (22659020)
- Scientific Research on Innovative Areas ‘Chemical Biology of Natural Products’ (24102502)
- Scientific Research (B) (25293026)
This publication has 16 references indexed in Scilit:
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- The resistance mechanisms of proteasome inhibitor bortezomibBiomarker Research, 2013
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or LymphomaClinical Cancer Research, 2012
- Proteasome Inhibitors: An Expanding Army Attacking a Unique TargetChemistry & Biology, 2012
- Convergent Synthesis and Biological Evaluation of Syringolin A and Derivatives as Eukaryotic 20S Proteasome InhibitorsEuropean Journal of Organic Chemistry, 2010
- Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibitionProceedings of the National Academy of Sciences, 2009
- Molecular mechanisms of proteasome assemblyNature Reviews Molecular Cell Biology, 2009
- A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanismNature, 2008
- Approval Summary for Bortezomib for Injection in the Treatment of Multiple MyelomaClinical Cancer Research, 2004
- Syringolin, a Novel Peptide Elicitor from Pseudomonas syringae pv. syringae that Induces Resistance to Pyricularia oryzae in RiceMolecular Plant-Microbe Interactions®, 1998